Linkedin Youtube
Launch Digital Edition

Webinars and Sponsored Roundtables — Register Now

Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.

Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Tuesday, November 10, 2026, 1 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.

Webinar presenter Jeffrey Gregg, MD, University of Nevada

CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.

Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs

CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Wednesday, December 9, 2026, 12 PM-1 PM ET
Hear an expert pathologist discuss the role of HER2 IHC testing and scoring in solid tumors including endometrial, ovarian, cervical, bladder, non-small cell lung, colorectal, and biliary cancers

Webinar presenter Michelle Shiller, DO, MSPT, Baylor Sammons Cancer Center; Fulgent Genetics; Texas Cancer Interception Institute

CAP TODAY does not endorse any of the products or services named within. This program is intended for US healthcare professionals. This program is being sponsored by AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Subspecialties

Interactive Product Guides

Manage Subscription

To receive CAP TODAY magazine, please subscribe here.
For change of address, mail new information to: CAP TODAY Circulation, 325 Waukegan Road, Northfield, IL 60093-2750 or visit here.

Marketplace

CE-IVD-marked TaqPath respiratory viral panel

August 2022—Thermo Fisher Scientific has launched its Applied Biosystems TaqPath Respiratory Viral Select panel. The CE-IVD-marked molecular assay panel provides results in approximately three hours and tests for adenovirus, human metapneumovirus, rhinovirus/enterovirus, and parainfluenza virus using PCR technology. RNase P and positive controls are included to offer sample-to-result reliability. The solution is scalable, allowing laboratories to run from one to 94 samples simultaneously.

Reference materials for urine chemistry, bilirubin assays

August 2022—Verichem Laboratories now offers a range of liquid-stable and ready-to-use biosynthetic clinical reference materials for use with urine chemistry assays and designed for system calibration and calibration verification testing on a variety of clinical testing platforms, including from Abbott, Beckman Coulter, Roche, and Siemens Healthineers.

Bruker launches NMR-based long COVID test

August 2022—Bruker Corp. has launched PhenoRisk PACS RuO, a research use only nuclear magnetic resonance test for molecular phenomics research on blood samples of patients with post-acute COVID syndrome (PACS), or long COVID. The test uses a multiplexed combination of biomarkers and is for research on early-stage risk factors on longitudinal recovery monitoring and on potential secondary organ damage in cardiovascular disease, type 2 diabetes, kidney dysfunction, and inflammation. It runs on the Avance IVDr NMR spectroscopy system, which produces results in 20 minutes.

CSF false-bottom tube

August 2022—Sarstedt announced the availability of a false-bottom tube for cerebrospinal fluid with an elevated conical base. The tube was developed and validated for Roche, specifically for use with Roche’s new generation of Elecsys immunoassays designed to detect Alzheimer’s disease biomarkers on Cobas e analyzers. The tubes are manufactured from medical-grade polypropylene and have HDPE screw caps that are leak resistant at 95 kilopascals.

EKF to distribute FDA-cleared Lucica glycated albumin test

July 2022—EKF Diagnostics announced the availability of the FDA-cleared Lucica Glycated Albumin-L test kit, manufactured by Asahi Kasei Pharma Corp. and sold exclusively in the United States by EKF. Lucica Glycated Albumin-L is a specific, quantitative test for glycated albumin for the intermediate-term monitoring of glycemic control in patients with diabetes.

Sarstedt launches web shop

July 2022—Sarstedt has launched a web shop for direct online ordering of its labware consumables, specimen collection devices, and small instruments. The shop is available to customers in the United States and can be accessed via the company website at www.sarstedt.com or directly at www.shop.sarstedt.us.

Seegene develops assay to detect monkeypox virus

July 2022—Seegene has developed a PCR test to detect monkeypox virus. The Novaplex MPXV assay, for research use only, was developed using the company’s AI-based automated test development system and can identify positive cases of the monkeypox virus in 90 minutes.

Steripath use studied hospitalwide

July 2022—Magnolia Medical Technologies, developers of the FDA 510(k)-cleared Steripath platform for reducing blood culture contamination for sepsis testing accuracy, announced the publication of results from a study performed by United Hospital Center, a member of the West Virginia University Health System.

BioMérieux Chikungunya dx tests get CE mark

July 2022—BioMérieux announced the CE marking of its Vidas Anti-Chikungunya IgM and Anti-Chikungunya IgG tests to diagnose Chikungunya virus infection. The tests can detect infection during the acute phase and into the chronic phase and run on the company’s Vidas immunoassay instruments.

MARKETPLACE

TRENDING